Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

307P - Impact of inflammatory index on the prognosis of cholangiocarcinoma in Mexican population

Date

27 Jun 2024

Session

Poster Display session

Presenters

Marytere Herrera

Citation

Annals of Oncology (2024) 35 (suppl_1): S119-S161. 10.1016/annonc/annonc1481

Authors

M. Herrera1, B. Carbajal1, P. Juarez Mejia1, G. Calderillo Ruiz1, M.D.C. Diaz Romero2, S. Zilli Hernández1, S.M. Miyagui Adame1, V. Salais Michaus1, J. Cervantes Bojalil1, A.W. Saenz Mamani3, E. Ruiz1

Author affiliations

  • 1 INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico/MX
  • 2 INCAN - Instituto Nacional de Cancerologia, 14080 - Ciudad de Mexico/MX
  • 3 ISSSTE Hospita Regional de alta especialidad bicentenario de la Independencia, Tultitlán/MX

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 307P

Background

Cholangiocarcinoma represents 3% of the gastrointestinal cancers. 65% are diagnosed at advanced stages of disease including clinical stages III and IV. Therapeutic approaches are limited. Due to the rareness of the disease, prognostic factors description remains unclear. This study aims to evaluate the impact of the inflammatory index on the prognosis of patients diagnosed with cholangiocarcinoma treated at the National Cancer Institute (INCan) Mexico.

Methods

Retrospective, observational study. Included patients treated at the INCan between 2014 and 2023. Statistical analysis required: X2 and t-test, Kaplan Meier, Log Rank, and Cox Regression. Statistical significance differences were assessed when p was bilaterally <0.05.

Results

A total of 222 patients were included in the analysis. 63% (n=140) were female, 84% (n=187) and the most frequent functional status was ECOG 2 (37.3%, n=83). 82% were adenocarcinoma (n=182), the most frequent clinical stage was IV (69%, n=153), with a prevalence of liver metastasis (51%, n=114). 46% (n=102) received chemotherapy, and 54% (n=150) had palliative care. Neutrophil/lymphocyte (INL), platelet/lymphocyte (IPL), neutrophil monocyte indices (IML), albumin, alkaline phosphatase (AF), and bilirubin were determined to evaluate their impact on prognosis. 69% had INL ≥3.15 mg/dl, 77% (n=171) IPL ≥106 mg/dl, and 79% (n=176) IML ≥0.24. Besides, 54% (n=119) had albumin ≥3.5 mg/dl, 71% (n=158) had AF ≥106 mg/dl, and 40% (n=89) had bilirubin ≥3.5 mg/dl. In overall survival (OS) analysis, patients with INL <3.15 had a median OS of 26m versus 11m (p=0.005), IPL <106 showed a median OS of 5m versus 3m (p =0.033), and IML <0.24 a median OS of 7m versus 3m (P= 0.014). Besides albumin 3.5 mg/dl had a median OS of 26m versus 10m (p=0.003), AF ≥106 mg/dl had a median OS of 50m versus 10m (p≤0.001), and bilirubin median OS of 17m (p=0.359). In uni-multivariate analysis, INL (p=0.030; HR 1.74, 95% IC 1.05 – 2.87) and AF (p=0.002; HR 0.35, 95% IC 0.18 – 0.67) remained predictor factors of OS.

Conclusions

In the prognosis assessment of this population, INL and AF remained predictor factors of OS. This is one of the first studies in Mexico to describe clinicopathological features and how these index correlates with the of OS of cholangiocarcinoma.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.